• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

ASI UK Income Equity Fund I Acc

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund ProviderAberdeen Standard Fund Managers Limited
Fund SummaryTo generate income and some capital over the long term (5 years or more) by investing in UK equities (company shares).Performance Target: To achieve the return of the FTSE All-Share Index plus 3% per annum over three years (before charges). The Performance Target is the level of performance that the management team hopes to achieve for the fund. There is however no certainty or promise that they will achieve the Performance Target.The ACD believes this is an appropriate target for the fund based on the investment policy of the fund and the constituents of the index.
SEDOL codeB0XWN92
ISINGB00B0XWN929
Fund codeABEQT
ManagersCharles Luke
Manager Tenure4 years
Morningstar CategoryUK Equity Income
IMA SectorUK Equity Income
Fund Size£146 million
Fund TypeOEIC
Management StyleActive
Ongoing Charge Figure (OCF)0.87%
Cavendish ongoing charge0.05%
FundsNetwork Service Fee0.20%
Minimum Initial Investment£25
Minimum Top Up£25
Minimum Monthly Investment£25
Sell Price£13.0132
Buy Price£13.0132
Price Change-1.2962%
Price Date25th September 2020
Yield4.14%
Dividend FrequencySemi-Annually
ISA EligibleYes
SIPP EligibleYes
Inception Date30th May 2013
Fund StatusOPEN
Charles Luke is an Investment Director in the UK Equity Team. His responsibilities include managing the Murray Income Trust and the ASI UK Income Equity Fund alongside the team’s Long Term Quality income strategies and other funds. In addition, he is also responsible for analysing the Business Support Services, Gas & Electricity, Health Equipment & Services sectors. Charles originally joined Aberdeen Asset Management in 2000. Charles started his career at Framlington Investment Management in 1998, covering UK equities

3-year Mean Monthly Return: 0.190%

Annual Returns2019201820172016201520142013201220112010
Fund Performance-4.37%+4.67%+1.41%+18.04%-0.50%-1.33%+11.50%+20.22%+1.58%+26.72%
Benchmark Performance
(UK Equity Income)
-14.88%-2.76%+5.09%+18.47%-1.43%
Time PeriodCumulativeBenchmark Performance
(UK Equity Income)
Fund Compared to Benchmark
1 day-1.30%-23.91%+22.61%
1 week-4.02%-5.07%+1.05%
1 month-3.92%-3.75%-0.17%
3 months-1.94%+8.18%-10.13%
6 months12.41%-17.30%+29.72%
1 year-7.03%-5.55%-1.48%
3 years0.73%+0.24%+0.49%
5 years4.56%+5.00%-0.44%
10 years5.76%+8.26%-2.49%
YTD-14.93%-3.99%-10.94%
Since inception8.23%Currently unavailableCurrently unavailable

Top 10 shares for this fund

Share NameCountryValue
AstraZeneca PLCGBR4.49%
Unilever PLCGBR3.89%
Diageo PLCGBR3.72%
GlaxoSmithKline PLCGBR3.46%
BHP Group PLCGBR3.36%
Rio Tinto PLCGBR3.32%
RELX PLCGBR3.18%
AVEVA Group PLCGBR3.13%
National Grid PLCGBR2.88%
British American Tobacco PLCGBR2.69%
Dividend DatePer share amountReinvestment Price
3rd August 20200.2947£13.0870
3rd February 20200.2485£15.1213
1st August 20190.3459£14.2903
1st February 20190.2175£12.6049
1st August 20180.3209£13.4736
1st February 20180.1796£13.0730